VEURINK; Marieke
Patent Applications and Registrations
Patent applications and USPTO patent grants for VEURINK; Marieke.The latest application filed is for "novel stable high-concentration formulation for anti-fxia antibodies".
- VEURINK; Marieke - Hamburg DE
- Veurink; Marieke - Geneva CH
- Veurink; Marieke - Geneve CH
| Patent | Date |
|---|---|
| NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES App 20210292434 - GOMBERT; Niklas ; et al. | 2021-09-23 |
| Novel Stable Formulation For Fxia Antibodies App 20190367636 - OLBRICH; Carsten ; et al. | 2019-12-05 |
| Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs Grant 9,155,745 - Gurny , et al. October 13, 2 | 2015-10-13 |
| Stabilized Antibody Preparations And Uses Thereof App 20130028920 - Gurny; Robert ; et al. | 2013-01-31 |
| Stabilized Antibody Preparations And Uses Thereof App 20130017197 - Gurny; Robert ; et al. | 2013-01-17 |
| Antibody Formulations and Use Thereof App 20100316638 - Gurny; Robert ; et al. | 2010-12-16 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 